This is a routine initial ownership filing with no trading or corporate action. No immediate trading signal. Monitor for any subsequent Form 4 filings or IPO-related conversion events.
Price Chart
Executive Summary
Edward M. Fitzgerald filed a Form 3 initial statement of beneficial ownership with the SEC, disclosing stock options and convertible preferred stock holdings in Parabilis Medicines, Inc. This is a routine SEC filing required upon becoming an insider; it contains no material financial events or changes in the company's operations.
Key Facts
- Filing type: Form 3 (initial statement of beneficial ownership) filed by Edward M. Fitzgerald.
- Discloses stock options to buy: 16,245 shares at $1.85 (expiring 2027-07-30), 16,245 shares at $4.82 (expiring 2031-05-12), 32,490 shares at $3.14 (expiring 2036-02-23).
- Holds convertible Series B Preferred (5,539 shares common underlying), Series C Preferred (3,878 shares common underlying), and Series F Preferred (5,271 shares common underlying).
- Conversion ratios: Series B 1:1.0389, Series C 1:1.0578, Series F 1:0.6498; all automatically convert to common stock upon IPO closing.
- Filed concurrently with a Limited Power of Attorney designating Teresa Jurgensen and Thomas Kotarakos to execute future Section 16 filings.
Financial Impact
No monetary value disclosed; the options and preferred shares represent insider equity holdings. No transaction or cash flow involved.
Risk Factors
- No material risks identified from this filing alone.
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001193125-26-264573 |
| Document: 0001193125-26-264573-index-headers.html | 0001193125-26-264573 |
| Document: 0001193125-26-264573-index.html | 0001193125-26-264573 |
| Document: 0001193125-26-264573.txt | 0001193125-26-264573 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 24, 2026 2d ago | Press Release | $24.79 | awaiting T+60 | — | $25.13 (+1.37%) |
Oct 19, 2026 7d ago | Press Release | $25.35 | awaiting T+60 | — | $25.13 (−0.87%) |
Sep 15, 2026 5w ago | 8-K | $36.88 | awaiting T+60 | — | $25.13 (−31.86%) |
Sep 2, 2026 7w ago | 8-K | $40.75 | awaiting T+60 | — | $25.13 (−38.33%) |
Aug 13, 2026 10w ago | 8-K | $35.67 | awaiting T+60 | — | $25.13 (−29.55%) |
Aug 13, 2026 10w ago | Press Release | $35.67 | awaiting T+60 | — | $25.13 (−29.55%) |
Jul 22, 2026 13w ago | Insider Buy | $32.81 $22.75 | ▼ −30.66% | ▼ −34.31% | $25.13 (−23.41%) |
Jun 29, 2026 17w ago | Insider Cluster | $29.19 $33.31 | ▲ +14.11% | ▲ +10.50% | $25.13 (−13.91%) |
Jun 16, 2026 18w ago | Insider Cluster | $26.03 $36.16 | ▲ +38.92% | ▲ +36.23% | $25.13 (−3.46%) |
Jun 15, 2026 18w ago | Insider Cluster | $26.59 $36.88 | ▲ +38.70% | ▲ +36.84% | $25.13 (−5.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers